SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
Breast cancer risk significantly lower at median follow - up of 131 months; effect continued after treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pharmacy, Conference News, Source Type: news

SABCS: Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
TUESDAY, Dec. 17, 2019 -- Anastrozole is associated with a long-term reduction in breast cancer risk, even after treatment, according to a study published online Dec. 12 in The Lancet to coincide with the annual San Antonio Breast Cancer Symposium,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Drug that halves a woman's risk of breast cancer works for SEVEN YEARS after they stop taking it
Arimidex halves the risk of breast cancer in postmenopausal women. Now, a study at Queen Mary University of London shows these effects last for a further seven years. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2019 Category: Consumer Health News Source Type: news

Drug that prevents half of breast cancers carries on working
Anastrozole is available already, but doctors say substantially more women should be taking it. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 12, 2019 Category: Consumer Health News Source Type: news

Anastrozole Shows Long-Lasting Breast Cancer Prevention Power
THURSDAY, Dec. 12, 2019 -- Nearly six years after stopping a five-year regimen of the breast cancer drug anastrozole, women at high risk for breast cancer were 50% less likely to have been struck by the disease, new research shows. The trial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 12, 2019 Category: General Medicine Source Type: news

IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women
(Queen Mary University of London) The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news

Long-Term Follow-Up Supports Anastrozole Treatment to Prevent Breast Cancer Recurrence
Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Riskreducing medications for primary breast cancer: a network metaanalysis
This Cochrane Review of 6 studies (n=50,927 on 1 cancer prevention agent (CPA:tamoxifen/raloxifene/exemestane/anastrozole] or placebo) found for women at above ‐average risk of developing breast cancer, CPAs can reduce incidence of this disease. Aromatase inhibitors appear to be more effective. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news

Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer
More than six years after a study showed that women with hormone-receptor-positive metastatic breast cancer benefit from a combination of anastrozole and fulvestrant, extended results show the trend has become even more pronounced, but mostly for women not previously exposed to tamoxifen.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Fulvestrant plus anastrozole extends lives of women with advanced HR+ breast cancer
(SWOG) Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, fulvestrant and anastrozole, compared with treatment with anastrozole alone, according to results of a SWOG Cancer Research Network study appearing in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: news

Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

Drug combination effective to treat male infertility
Combination therapy of drugs clomiphene citrate and anastrozole is a safe and effective way to treat infertility in males, a study inBJU International suggests.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 6, 2018 Category: Endocrinology Source Type: news

Combination drug therapy effectively treats male infertility
(Wiley) Two drugs that are commonly used off-label in the treatment of male infertility are clomiphene citrate (CC) and anastrozole (AZ); however, data are lacking on the use of combination CC+AZ therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 6, 2018 Category: International Medicine & Public Health Source Type: news

Anastrozole vs. Letrozole
Title: Anastrozole vs. LetrozoleCategory: MedicationsCreated: 12/14/2017 12:00:00 AMLast Editorial Review: 12/14/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 14, 2017 Category: Drugs & Pharmacology Source Type: news

Only 2 Years of Extended Anastrozole Needed in Breast Cancer Only 2 Years of Extended Anastrozole Needed in Breast Cancer
After an initial 5 years of endocrine therapy in postmenopausal cancer, a further 2 years of the aromatase inhibitor is sufficient, instead of another 5 years, suggest new results.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SABCS: Two Years of Anastrozole Sufficient in HR + Early Breast CA
No significant difference in DFS for women receiving anastrozole for two, five years after endocrine tx (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Breast cancer screening has ‘little impact’ on cancer deaths
Over-diagnosis of cases is rising, warns study Related items fromOnMedica Experts recommend anastrozole for postmenopausal women with family history of breast cancer The genetics of breast cancer NICE approves breakthrough breast cancer drugs Breast cancer screening Breast cancer screening reduces risk of death (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 6, 2017 Category: UK Health Source Type: news

NICE approves breakthrough breast cancer drugs
New class of cancer treatment drugs approved for NHS Related items fromOnMedica The genetics of breast cancer Ovarian cancer drug may help stall breast cancer Experts recommend anastrozole for postmenopausal women with family history of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 16, 2017 Category: UK Health Source Type: news

Genetic test may help fight secondary breast cancer
Study shows benefits of using bone strengthening drugs Related items fromOnMedica Big data advances breast cancer research by ‘decades’ Experts recommend anastrozole for postmenopausal women with family history of breast cancer Women with incurable breast cancer receiving insufficient care Research reveals age-specific cancer risk with BRCA1/2 The genetics of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 24, 2017 Category: UK Health Source Type: news

NICE set to approve trastuzumab emtansine for breast cancer
NHS England will routinely fund Kadcyla for people with advanced HER-2 positive cancer Related items fromOnMedica Ovarian cancer drug may help stall breast cancer The medicine price debate Breast cancer drug ‘too costly’ for NHS Experts recommend anastrozole for postmenopausal women with family history of breast cancer Cancer-preventing drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 16, 2017 Category: UK Health Source Type: news

Ovarian cancer drug may help stall breast cancer
Trial results with olaparib are ‘encouraging’ Related items fromOnMedica Breast cancer Big data advances breast cancer research by ‘decades’ Women with incurable breast cancer receiving insufficient care Cancer-preventing drugs Experts recommend anastrozole for postmenopausal women with family history of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 5, 2017 Category: UK Health Source Type: news

NICE: anastrozole for some women at risk of breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2017 Category: Drugs & Pharmacology Source Type: news

Experts recommend anastrozole for postmenopausal women with family history of breast cancer
Doctors should offer it to women at moderate risk of breast cancer Related items fromOnMedica Fertility treatments may impact on breast cancer risk Work needed to boost GPs ’ knowledge of cancer drug Cancer-preventing drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 23, 2017 Category: UK Health Source Type: news

Arimidex (Anastrozole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 4, 2017 Category: Consumer Health News Source Type: news

NHS to offer breast cancer prevention treatment pill for 4p-a-day
Prescribing watchdogs the National Institute for Health and Care Excellence said the drug, anastrozole, should be available to women who are over 50 and deemed to have a high risk. (Source: the Mail online | Health)
Source: the Mail online | Health - December 4, 2016 Category: Consumer Health News Source Type: news

Anastrozole recommended for prevention of breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2016 Category: Drugs & Pharmacology Source Type: news

Older DCIS Patients Have Low Rates of Tamoxifen, AI Usage
The initiation of and adherence to tamoxifen or aromatase inhibitors (AIs) such as anastrozole is low among older women with estrogen receptor-positive ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

ASCO: Clinical and QOL Benefits With Arimidex in Endometrial Ca (CME/CE)
(MedPage Today) -- 44% clinical benefit rate, median PFS of 3.2 months in recurrent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2016 Category: Hematology Source Type: news

AstraZeneca finds faslodex better than arimidex in treating metastatic breast cancer
AstraZeneca has found that faslodex 500mg (fulvestrant) is demonstrating better results than arimidex 1mg (anastrozole) while treating locally-advanced or metastatic breast cancer in post-menopausal women, who have not had prior hormonal treatment fo… (Source: Drug Development Technology)
Source: Drug Development Technology - May 31, 2016 Category: Pharmaceuticals Source Type: news

Which Medication is More Cost Effective?
Tamoxifen and Arimidex are two hormone therapy drugs that are commonly prescribed to prevent recurrence of hormone-sensitive breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 15, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Prioritizing Patients Over Profits
Imagine a pharmaceutical company that distributes all profits to patient support and medical research... Enter For Benefit Medicines (FBM), established by Dr Barry Frost, in partnership with John Hurley. Frost holds a PhD in pharmacology and has spent 35 years working for four different major pharmaceutical companies. With a rich and varied experience in pharma, it has been the ‘for benefit’ model that has interested him most over the past few years. After reading an article in the Harvard Business Review (November 2011 edition) entitled “The For Benefit Enterprise,” Frost was intrigued by...
Source: EyeForPharma - January 25, 2016 Category: Pharmaceuticals Authors: Dr Nicola Davies Source Type: news

Drug Trials in DCIS Almost a Wash (CME/CE)
(MedPage Today) -- Patient preference in side effects likely to influence choice of Arimidex or Nolvadex (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 14, 2015 Category: Journals (General) Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 12, 2015 Category: Cancer & Oncology Source Type: news

AI vs Tamoxifen for DCIS? A Toss-up, Unless…AI vs Tamoxifen for DCIS? A Toss-up, Unless…
Both anastrozole and tamoxifen were effective at preventing recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ. Age, toxicities should drive choice, say investigators. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Anastrozole is as effective as current breast cancer drugs with fewer side effects
Post-menopausal women taking anastrozole experienced fewer womb, ovarian and skin cancers and fewer gynaecological symptoms, according to a study led by Queen Mary University. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2015 Category: Consumer Health News Source Type: news

For women taking 2 leading breast cancer drugs, symptoms tend to vary by patient’s age
UCLA Jonsson Comprehensive Cancer Center Dr. Patricia Ganz A study of two leading breast cancer drugs has determined that the breast cancer symptoms women experience while taking those drugs — and the severity of those symptoms — tend to vary based on the patients’ ages. The findings could be an important step toward personalized medicine for women with breast cancer, said Dr. Patricia Ganz, director of the UCLA Jonsson Comprehensive Cancer Center’s Prevention and Control Research program and the study’s first author. The study examined data for 1,193 postmenopausal women with a type of breas...
Source: UCLA Newsroom: Health Sciences - December 11, 2015 Category: Universities & Medical Training Source Type: news

Drug provides another treatment option for an early form of breast cancer
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial. The results of the trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer’s Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: WebMD Health)
Source: WebMD Health - December 11, 2015 Category: Consumer Health News Source Type: news

Drug provides another treatment option for an early form of breast cancer
(Queen Mary, University of London) The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen
(American Association for Cancer Research) Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
(American Association for Cancer Research) Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects, according to results from the phase III IBIS-II DCIS clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

Breast Cancer Survival Improved With Arimidex (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 2, 2015 Category: Geriatrics Source Type: news

ASCO: Arimidex Ups 10-Year Survival Rate in DCIS (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 1, 2015 Category: Geriatrics Source Type: news

Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 1, 2015 Category: Science Source Type: news

Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
(Loyola University Health System) Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2015 Category: Cancer & Oncology Source Type: news

Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be followed more closely,...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news

Fulvestrant Survival Advantage in Advanced Breast CancerFulvestrant Survival Advantage in Advanced Breast Cancer
New survival data from the FIRST trial show a survival advantage for the injectable fulvestrant over the standard of care, oral anastrozole. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

anastrozole (Arimidex)
Title: anastrozole (Arimidex)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/3/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 3, 2014 Category: Drugs & Pharmacology Source Type: news